capecitabine has been researched along with sulindac in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH | 1 |
1 review(s) available for capecitabine and sulindac
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for capecitabine and sulindac
| Article | Year |
|---|---|
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 5; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Phosphoric Diester Hydrolases; Prodrugs; Sulindac | 2003 |
1 other study(ies) available for capecitabine and sulindac
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |